Weak US Sentiment Hits Novonesis
Novonesis reports an eight percent drop in human health revenue due to weak US dietary supplement sales. CEO Ester Baiget expects the North American market to recover by late 2027.
Perspectivas:
Weak United States consumer sentiment cut Novonesis Human Health revenue 8% in the third quarter, offsetting broader organic growth. The biotech firm expects the North American dietary supplement market to recover by the second half of 2027. Citing shifting buyer behavior, CEO Ester Baiget noted that offline retail declines in North America weighed on regional performance.
